Transthyretin Amyloidosis Treatment Market Outlook 2025-2034: Key Trends, Growth Drivers, and Market Share

What market dynamics are playing a key role in accelerating the growth of the transthyretin amyloidosis treatment market?
The anticipated surge in the transthyretin amyloidosis treatment market can be attributed to escalating investments in research and development. These investments cover financial resources directed towards scientific advances, novel technologies, creation of innovative products, and enhancement of existing processes. Such a rise in funding allows the identification and cultivation of new methods for treating transthyretin amyloidosis, encompassing revolutionary drugs, gene therapies, and precision medicine offerings, thereby providing patients with more effective and specified treatments. For example, Alnylam Pharmaceuticals, a US biopharmaceutical firm known for the development of Vutrisiran (an ATTR amyloidosis treatment) boosted its R&D investment to $883,015 in 2022 from $792,156 in 2021 marking an 11.49% increase. Thus, this escalating investment in research is likely to spur the growth of the transthyretin amyloidosis treatment market. An increase in the elderly population is another factor predicted to fuel the transthyretin amyloidosis treatment market's growth. The term aging population denotes a demographic shift in which there is an increase in the average age of a population due to reduced fertility rates and longer life spans. Age is a key risk indicator for ATTR amyloidosis, and as people get older, the number of Transthyretin Amyloidosis cases increases, thus widening the pool of patients requiring treatment. It's noted in October 2022 by the World Health Organization, a global health authority under the United Nations, that every country experiences an amplification in the number and ratio of older people in their populations. By 2030, it's projected that 1 in 6 people globally will be 60 years or older. Therefore, the increasing aging population is another factor propelling the transthyretin amyloidosis treatment market's growth.

Get Your Transthyretin Amyloidosis Treatment Market Report Here:
https://www.thebusinessresearchcompany.com/report/transthyretin-amyloidosis-treatment-global-market-report

How will the growth rate of the transthyretin amyloidosis treatment market shape industry trends by 2034?
The market for treatment of transthyretin amyloidosis has seen substantial growth in the past, and it's projected to further expand from a value of $5.52 billion in 2024 to an estimated $5.95 billion by 2025, with a compound annual growth rate (CAGR) of 7.8%. This historical market growth can be traced back to factors such as improved awareness of the disease, progression in diagnostic techniques, development and approval of new drugs, proactive patient advocacy and support, as well as collaborative research.

In the coming years, the transthyretin amyloidosis treatment market is projected to witness robust expansion. By 2029, the market is forecasted to reach $8.04 billion, with a compound annual growth rate (CAGR) of 7.8%. The growth during the predicted period can be credited to the extended therapeutic pipeline, amplified genetic screening, global undertakings toward rare disease awareness, the use of personalized medicine strategies, and bettered access to treatment. The forecast period will also experience significant shifts including the appearance of combination therapies, the forming of strategic alliances for drug invention, concentration on targeting peripheral and cardiac symptoms, the application of patient instruction programs, and the inclusion of real-world evidence in treatment guidelines.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13129&type=smp

What trends are poised to drive the future success of the transthyretin amyloidosis treatment market?
Leading players within the transthyretin amyloidosis treatment market are concentrating on evolving innovative and specialized therapies, such as orphan drugs, to ramp up patient outcomes and augment treatment possibilities. Eplontersen is a distinctive orphan drug developed to treat transthyretin amyloidosis, often getting regulatory incentives for its evolution. For example, in March 2023, Ionis Pharmaceuticals, Inc., a biotechnology research corporation based in Canada, attained The Food and Drug Administration (FDA) approval for a new drug application for Eplontersen, an innovative orphan drug targeted for treating familial transthyretin-mediated amyloid, which results in progressive polyneuropathy. Eplontersen is a medicinal product formulated to lessen the production of transthyretin (TTR) protein, addressing both inherited and non-inherited forms of ATTR amyloidosis (amyloid transthyretin amyloidosis). In 2022, the FDA sanctioned an orphan drug designation for Eplontersen.

Which primary segments of the transthyretin amyloidosis treatment market are driving growth and industry transformations?
The transthyretin amyloidosis treatment market covered in this report is segmented -

1) By Type: Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
2) By Drug: Tafamidis, Patisiran, Inotersen, Other Drugs
3) By Therapy: Targeted Therapy, Supportive Therapy, Pipeline Therapy
4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN): Early-Stage ATTR-PN, Advanced-Stage ATTR-PN
2) By Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM): Mild ATTR-CM, Moderate ATTR-CM, Severe ATTR-CM

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13129

North America was the largest region in the transthyretin amyloidosis treatment market in 2024. The regions covered in the transthyretin amyloidosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Who are the influential players reshaping the transthyretin amyloidosis treatment market landscape?
Major companies operating in the transthyretin amyloidosis treatment market report are Pfizer Inc., Abbvie Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, GSK PLC, Novo Nordisk A/S, Merck & Co. Inc., Astellas Pharma Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics, Ionis Pharmaceuticals, Prothena Corporation PLC, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Intellia Therapeutics, Akcea Therapeutics Inc., Eidos Therapeutics Inc., Acrotech Biopharma Inc., Spectrum Pharmaceuticals Inc., Neurimmune AG, BELLUS Health Inc., Corino Therapeutics Inc., Celgene Corp, SOM Innovation Biotech S.A

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=13129&type=smp

What Is Covered In The Transthyretin Amyloidosis Treatment Global Market Report?

•Market Size Forecast: Examine the transthyretin amyloidosis treatment market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the transthyretin amyloidosis treatment market for a structured understanding.
•Key Players Overview: Analyze major players in the transthyretin amyloidosis treatment market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the transthyretin amyloidosis treatment market.
•Segment Contributions: Evaluate how different segments drive overall growth in the transthyretin amyloidosis treatment market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the transthyretin amyloidosis treatment market.
•Industry Challenges: Identify potential risks and obstacles affecting the transthyretin amyloidosis treatment market.
•Competitive Landscape: Review strategic developments in the transthyretin amyloidosis treatment market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.